Grufity logo
Grufity logo
SLNO

SLNO - Soleno Therapeutics Inc Stock Price, Fair Value and News

$53.01 
Market Closed as of 18 May 2026, 04:00 pm ET

Price Targets

SLNO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SLNO Price Action

Last 7 days

0.1%

Last 30 days

0.8%

Last 90 days

42.4%

Trailing 12 Months

-29.4%

SLNO RSI Chart

SLNO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SLNO Valuation

Market Cap

2.8B

Price/Earnings (Trailing)

28.76

Price/Sales (Trailing)

9.69

EV/EBITDA

95.07

Price/Free Cashflow

26.21

SLNO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

SLNO Fundamentals

SLNO Revenue

Revenue (TTM)

285.0M

SLNO Earnings

Earnings (TTM)

96.1M

Earnings Growth (Yr)

171.73%

Earnings Growth (Qtr)

-27.58%

SLNO Profitability

Operating Margin

98.64%

EBT Margin

7.33%

Return on Equity

19.38%

Return on Assets

15.79%

Free Cashflow Yield

3.82%

SLNO Investor Care

Shares Dilution (1Y)

3.43%

Diluted EPS (TTM)

1.87

Revenue & Growth

How Soleno Therapeutics Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026285.0M---
2025---190.4M
2024----
2023----
2022----
2021----
2019200.0M200.0M200.0M-
2018200.0M200.0M200.0M200.0M
20171.3M67.5M133.8M200.0M
2016812.6K1.1M1.2M1.5M
20152.3M1.7M1.0M387.6K
2013---3.0M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Soleno Therapeutics Inc

SLNO
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
 CEO
 WEBSITEhttps://soleno.life
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES25

Soleno Therapeutics Inc Frequently Asked Questions

SLNO is the stock ticker symbol of Soleno Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon May 18 2026, market cap of Soleno Therapeutics Inc is 2.76 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon May 18 2026, SLNO's PE ratio (Price to Earnings) is 28.76 and Price to Sales (PS) ratio is 9.69. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SLNO PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Soleno Therapeutics Inc has provided -0.044 (multiply by 100 for percentage) rate of return.